Full Press Release Details
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
“Our intent to separate our wholly owned biopharma programs from our royalty assets provides investors with the opportunity to realize and enhance the potential value of two distinct sets of assets.Jemperlisales grew to $785 million YTD with GSK indicating dMMR endometrial market share is now ~5% greater than Keytruda1, reflectingJemperli’sdifferentiated overall survival data and supporting GSK’s peak sales guidance of far more than $2.7 billion2in monotherapy indications,” said Daniel Faga, president and chief executive officer of Anaptys. “Our biopharma portfolio is strategically positioned with multiple attractive, high-potential assets, including rosnilimab, ANB033 and ANB101. Rosnilimab’s transformational profile was highlighted in a late-breaking presentation of Phase 2b data in RA at ACR Convergence 2025 and we anticipate reporting top-line Phase 2 data through Week 12 in ulcerative colitis in November or December.”INTENT TO SEPARATE BUSINESS
ROYALTY MANAGEMENT CO
GSKJemperliFinancial Collaboration
Vanda Imsidolimab Financial Collaboration
BIOPHARMA CO
Rosnilimab (Pathogenic T Cell Depleter)
ANB033 (CD122 antagonist)
ANB101 (BDCA2 modulator)
FINANCIAL UPDATES
Stock Repurchase Program and Cash Runway
Third Quarter 2025 Financial Results
About AnaptysAnaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication. Additionally, ANB101, a BDCA2 modulator, is in a Phase 1a trial. Anaptys also has discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli(dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visitwww.AnaptysBio.comor follow us onLinkedIn.Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn morehere.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company’s clinical trials, including rosnilimab’s top-line Phase 2 clinical trial data in ulcerative colitis and ANB033’s phase 1b cohort in celiac disease; whether positive clinical trial results in rosnilimab’s Phase 2b clinical trial in rheumatoid arthritis increases the likelihood of getting positive results from rosnilimab’s Phase 2 clinical trial in ulcerative colitis; expectations regarding the structure, infrastructure, timing and taxation of the proposed separation of companies; timing of paydown of financial obligations to Sagard; timing of initiation of Phase 1b clinical trial in second indication with ANB033; the potential to receive any royalties or milestone payments from the Vanda Pharmaceuticals license agreement; the potential to receive any additional milestones and royalties from the GSK collaboration and the timing therefor; and the projected cash runway for Biopharma Co. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.Contact:Nick MontemaranoExecutive Director, Investor Relations858.732.0178investors@anaptysbio.com_______________________________________
| AnaptysBio, Inc.Consolidated Balance Sheets(in thousands, except par value data)(unaudited) | |||||||
| September 30, 2025 | December 31, 2024 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 109,833 | $ | 123,080 | |||
| Receivables from collaborative partners | 75,685 | 40,765 | |||||
| Short-term investments | 139,123 | 262,293 | |||||
| Prepaid expenses and other current assets | 6,009 | 5,738 | |||||
| Total current assets | 330,650 | 431,876 | |||||
| Property and equipment, net | 1,500 | 1,849 | |||||
| Operating lease right-of-use assets | 12,994 | 14,383 | |||||
| Long-term investments | 7,698 | 35,470 | |||||
| Other long-term assets | 256 | 256 | |||||
| Total assets | $ | 353,098 | $ | 483,834 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 2,893 | $ | 4,002 | |||
| Accrued expenses | 33,171 | 39,501 | |||||
| Current portion of operating lease liability | 2,040 | 1,925 | |||||
| Total current liabilities | 38,104 | 45,428 | |||||
| Liability related to sale of future royalties | 331,844 | 353,426 | |||||
| Operating lease liability, net of current portion | 12,566 | 14,112 | |||||
| Stockholders’ (deficit) equity: | |||||||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2025 and December 31, 2024, respectively | — | — | |||||
| Common stock, $0.001 par value, 500,000 shares authorized, 27,575 shares and 30,473 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 28 | 30 | |||||
| Additional paid in capital | 792,682 | 829,860 | |||||
| Accumulated other comprehensive gain | 47 | 305 | |||||
| Accumulated deficit | (822,173 | ) | (759,327 | ) | |||
| Total stockholders’ (deficit) equity | (29,416 | ) | 70,868 | ||||
| Total liabilities and stockholders’ (deficit) equity | $ | 353,098 | $ | 483,834 | |||
| AnaptysBio, Inc.Consolidated Statements of Operations and Comprehensive Income (Loss)(in thousands, except per share data)(unaudited) | |||||||||||||||
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Collaboration revenue | $ | 76,320 | $ | 30,017 | $ | 126,354 | $ | 48,167 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 31,407 | 42,212 | 110,411 | 121,251 | |||||||||||
| General and administrative | 10,209 | 10,562 | 34,948 | 32,195 | |||||||||||
| Total operating expenses | 41,616 | 52,774 | 145,359 | 153,446 | |||||||||||
| Income (loss) from operations | 34,704 | (22,757 | ) | (19,005 | ) | (105,279 | ) | ||||||||
| Other income (expense), net: | |||||||||||||||
| Interest income | 2,924 | 5,324 | 10,991 | 14,531 | |||||||||||
| Non-cash interest expense for the sale of future royalties | (22,515 | ) | (15,413 | ) | (60,182 | ) | (32,683 | ) | |||||||
| Other (expense) income, net | — | (5 | ) | 5,433 | (7 | ) | |||||||||
| Total other expense, net | (19,591 | ) | (10,094 | ) | (43,758 | ) | (18,159 | ) | |||||||
| Income (loss) before income taxes | 15,113 | (32,851 | ) | (62,763 | ) | (123,438 | ) | ||||||||
| Provision for income taxes | — | — | (83 | ) | (9 | ) | |||||||||
| Net income (loss) | 15,113 | (32,851 | ) | (62,846 | ) | (123,447 | ) | ||||||||
| Unrealized gain (loss) on available for sale securities | 53 | 1,174 | (258 | ) | 1,556 | ||||||||||
| Comprehensive income (loss) | $ | 15,166 | $ | (31,677 | ) | $ | (63,104 | ) | $ | (121,891 | ) | ||||
| Net income (loss) per common share: | |||||||||||||||
| Basic | $ | 0.54 | $ | (1.14 | ) | $ | (2.16 | ) | $ | (4.46 | ) | ||||
| Diluted | $ | 0.52 | $ | (1.14 | ) | $ | (2.16 | ) | $ | (4.46 | ) | ||||
| Weighted-average number of shares outstanding: | |||||||||||||||
| Basic | 27,833 | 28,893 | 29,085 | 27,688 | |||||||||||
| Diluted | 29,018 | 28,893 | 29,085 | 27,688 |